vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and INVESTORS TITLE CO (ITIC). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $69.5M, roughly 1.2× INVESTORS TITLE CO). On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -1.6%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $25.4M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 14.0%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
The Real Estate Title Insurance Company of Philadelphia was the world's first title insurance company.
FDMT vs ITIC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $69.5M |
| Net Profit | $19.4M | — |
| Gross Margin | — | — |
| Operating Margin | 17.3% | 13.8% |
| Net Margin | 22.8% | — |
| Revenue YoY | 8508900.0% | -1.6% |
| Net Profit YoY | 139.1% | — |
| EPS (diluted) | $0.43 | $3.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $69.5M | ||
| Q3 25 | $90.0K | $73.0M | ||
| Q2 25 | $15.0K | $73.6M | ||
| Q1 25 | $14.0K | $56.6M | ||
| Q4 24 | $1.0K | $70.6M | ||
| Q3 24 | $3.0K | $68.8M | ||
| Q2 24 | $5.0K | $65.4M | ||
| Q1 24 | $28.0K | $53.5M |
| Q4 25 | $19.4M | — | ||
| Q3 25 | $-56.9M | $12.2M | ||
| Q2 25 | $-54.7M | $12.3M | ||
| Q1 25 | $-48.0M | $3.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-43.8M | $9.3M | ||
| Q2 24 | $-35.0M | $8.9M | ||
| Q1 24 | $-32.4M | $4.5M |
| Q4 25 | 17.3% | 13.8% | ||
| Q3 25 | -67983.3% | 20.7% | ||
| Q2 25 | -396373.3% | 21.5% | ||
| Q1 25 | -383007.1% | 7.2% | ||
| Q4 24 | — | 15.3% | ||
| Q3 24 | -1704400.0% | 16.8% | ||
| Q2 24 | -849120.0% | 17.2% | ||
| Q1 24 | -136200.0% | 10.8% |
| Q4 25 | 22.8% | — | ||
| Q3 25 | -63195.6% | 16.7% | ||
| Q2 25 | -364386.7% | 16.7% | ||
| Q1 25 | -342657.1% | 5.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1461433.3% | 13.5% | ||
| Q2 24 | -699060.0% | 13.6% | ||
| Q1 24 | -115717.9% | 8.5% |
| Q4 25 | $0.43 | $3.97 | ||
| Q3 25 | $-1.01 | $6.45 | ||
| Q2 25 | $-0.98 | $6.48 | ||
| Q1 25 | $-0.86 | $1.67 | ||
| Q4 24 | — | $4.41 | ||
| Q3 24 | $-0.79 | $4.92 | ||
| Q2 24 | $-0.63 | $4.70 | ||
| Q1 24 | $-0.66 | $2.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $89.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $268.3M |
| Total Assets | $566.7M | $363.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | $89.6M | ||
| Q3 25 | $305.1M | $110.8M | ||
| Q2 25 | $293.2M | $90.1M | ||
| Q1 25 | $321.4M | $81.7M | ||
| Q4 24 | $424.9M | $83.8M | ||
| Q3 24 | $501.9M | $112.9M | ||
| Q2 24 | $541.9M | $111.2M | ||
| Q1 24 | $525.9M | $135.0M |
| Q4 25 | $505.7M | $268.3M | ||
| Q3 25 | $369.0M | $278.0M | ||
| Q2 25 | $420.9M | $266.2M | ||
| Q1 25 | $469.7M | $254.4M | ||
| Q4 24 | $510.6M | $251.8M | ||
| Q3 24 | $552.9M | $271.3M | ||
| Q2 24 | $588.3M | $261.8M | ||
| Q1 24 | $600.6M | $254.0M |
| Q4 25 | $566.7M | $363.1M | ||
| Q3 25 | $424.0M | $363.3M | ||
| Q2 25 | $473.6M | $345.8M | ||
| Q1 25 | $515.7M | $333.8M | ||
| Q4 24 | $560.4M | $333.6M | ||
| Q3 24 | $604.0M | $352.0M | ||
| Q2 24 | $620.1M | $340.3M | ||
| Q1 24 | $629.9M | $329.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $30.9M |
| Free Cash FlowOCF − Capex | $28.5M | $25.4M |
| FCF MarginFCF / Revenue | 33.5% | 36.5% |
| Capex IntensityCapex / Revenue | 0.1% | 8.0% |
| Cash ConversionOCF / Net Profit | 1.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $47.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $30.9M | ||
| Q3 25 | $-46.5M | $17.2M | ||
| Q2 25 | $-43.4M | $8.9M | ||
| Q1 25 | $-47.8M | $-75.0K | ||
| Q4 24 | $-134.6M | $29.8M | ||
| Q3 24 | $-29.4M | $7.8M | ||
| Q2 24 | $-30.2M | $8.4M | ||
| Q1 24 | $-29.1M | $1.4M |
| Q4 25 | $28.5M | $25.4M | ||
| Q3 25 | $-46.6M | $15.8M | ||
| Q2 25 | $-43.4M | $7.3M | ||
| Q1 25 | $-48.4M | $-1.4M | ||
| Q4 24 | $-138.4M | $22.4M | ||
| Q3 24 | $-31.2M | $6.1M | ||
| Q2 24 | $-30.6M | $6.3M | ||
| Q1 24 | $-29.8M | $-793.0K |
| Q4 25 | 33.5% | 36.5% | ||
| Q3 25 | -51765.6% | 21.7% | ||
| Q2 25 | -289620.0% | 9.9% | ||
| Q1 25 | -345635.7% | -2.5% | ||
| Q4 24 | -13837100.0% | 31.7% | ||
| Q3 24 | -1038966.7% | 8.8% | ||
| Q2 24 | -611840.0% | 9.7% | ||
| Q1 24 | -106421.4% | -1.5% |
| Q4 25 | 0.1% | 8.0% | ||
| Q3 25 | 101.1% | 1.8% | ||
| Q2 25 | 440.0% | 2.1% | ||
| Q1 25 | 4507.1% | 2.4% | ||
| Q4 24 | 378600.0% | 10.5% | ||
| Q3 24 | 59266.7% | 2.5% | ||
| Q2 24 | 6980.0% | 3.2% | ||
| Q1 24 | 2535.7% | 4.2% |
| Q4 25 | 1.47× | — | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | -0.02× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.95× | ||
| Q1 24 | — | 0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
